Top in allergy/asthma: FDA panel says oral PE ineffective; clinical remission in asthma
Click Here to Manage Email Alerts
An FDA advisory committee unanimously agreed that oral phenylephrine — an ingredient found in many nasal decongestants that are sold over the counter to treat colds and allergy symptoms — was no more effective than placebo.
It was the top story in allergy/asthma last week.
Two other top stories were about efforts to narrow down a definition of clinical remission in asthma.
Read these and more top stories in allergy/asthma below:
FDA panel deems ingredient in over-the-counter nasal decongestant ineffective
An FDA panel voted unanimously against the efficacy of oral phenylephrine, an ingredient in many nasal decongestants sold over the counter to treat colds and allergy symptoms. Read more.
Clinical remission of severe asthma ‘achievable goal’ with mepolizumab
Patients with severe asthma achieved clinical remission based on a four-component definition with 52 weeks of mepolizumab, according to an abstract presented at the European Respiratory Society International Congress. Read more.
Workgroup releases consensus definition for clinical remission in asthma on treatment
A multi-organizational panel has developed a working definition for clinical remission in asthma. Read more.
Omega-3 supplementation during pregnancy reduces infant risks for food allergy
Maternal omega-3 supplementation contributed to decreases in risks for food allergy among infants, including egg and peanut sensitization, according to a review published in The Journal of Allergy and Clinical Immunology: In Practice. Read more.
Wildfires have greater impact on patients with asthma, laryngeal hypersensitivity
Adults with asthma who also had laryngeal hypersensitivity had a greater symptom burden during the 2019 to 2020 landscape fires in Australia, according to a study. Two outside experts — J. Tod Olin, MD, MSCS, and Albert Rizzo, MD, FACP — offered their perspectives on the findings. Read more.